Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Breast Cancer

  Free Subscription


Articles published in Proc Natl Acad Sci U S A

Retrieve available abstracts of 84 articles:
HTML format



Single Articles


    October 2024

  1. Correction for Zhang et al., HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells.
    Proc Natl Acad Sci U S A. 2024;121:e2418194121.
    PubMed    


  2. ASEMOTA S, Effah W, Holt J, Johnson D, et al
    A molecular switch from tumor suppressor to oncogene in ER+ve breast cancer: Role of androgen receptor, JAK-STAT, and lineage plasticity.
    Proc Natl Acad Sci U S A. 2024;121:e2406837121.
    PubMed     Abstract available


    September 2024
  3. FENG X, Yang C, Huang Y, Su D, et al
    In vivo CRISPR screens identify Mga as an immunotherapy target in triple-negative breast cancer.
    Proc Natl Acad Sci U S A. 2024;121:e2406325121.
    PubMed     Abstract available


    August 2024
  4. CHIANG HC, Qi L, Mitra P, Huang Y, et al
    R-loop functions in Brca1-associated mammary tumorigenesis.
    Proc Natl Acad Sci U S A. 2024;121:e2403600121.
    PubMed     Abstract available


    July 2024
  5. SHAH OS, Nasrazadani A, Foldi J, Atkinson JM, et al
    Spatial molecular profiling of mixed invasive ductal and lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures, and mutations.
    Proc Natl Acad Sci U S A. 2024;121:e2322068121.
    PubMed     Abstract available


  6. ZIN I, China A, Khan K, Nag JK, et al
    AKT-dependent nuclear localization of EPRS1 activates PARP1 in breast cancer cells.
    Proc Natl Acad Sci U S A. 2024;121:e2303642121.
    PubMed     Abstract available


  7. ZHOU Q, Yu H, Chen Y, Ren J, et al
    The CRL3(KCTD10) ubiquitin ligase-USP18 axis coordinately regulates cystine uptake and ferroptosis by modulating SLC7A11.
    Proc Natl Acad Sci U S A. 2024;121:e2320655121.
    PubMed     Abstract available


    June 2024
  8. RUAN ML, Ni WX, Chu JCH, Lam TL, et al
    Iridium(III) carbene complexes as potent girdin inhibitors against metastatic cancers.
    Proc Natl Acad Sci U S A. 2024;121:e2316615121.
    PubMed     Abstract available


    May 2024
  9. CHEN J, Liu X, Zou Y, Gong J, et al
    A high-fat diet promotes cancer progression by inducing gut microbiota-mediated leucine production and PMN-MDSC differentiation.
    Proc Natl Acad Sci U S A. 2024;121:e2306776121.
    PubMed     Abstract available


  10. ASHOKAN A, Sarkar S, Kamran MZ, Surnar B, et al
    Simultaneous targeting of peripheral and brain tumors with a therapeutic nanoparticle to disrupt metabolic adaptability at both sites.
    Proc Natl Acad Sci U S A. 2024;121:e2318119121.
    PubMed     Abstract available


  11. GOYETTE MA, Stevens LE, DePinho CR, Seehawer M, et al
    Cancer-stromal cell interactions in breast cancer brain metastases induce glycocalyx-mediated resistance to HER2-targeting therapies.
    Proc Natl Acad Sci U S A. 2024;121:e2322688121.
    PubMed     Abstract available


    April 2024
  12. MONDAL DK, Xie C, Pascal GJ, Buraschi S, et al
    Decorin suppresses tumor lymphangiogenesis: A mechanism to curtail cancer progression.
    Proc Natl Acad Sci U S A. 2024;121:e2317760121.
    PubMed     Abstract available


    March 2024
  13. WANG D, Tang M, Zhang P, Yang K, et al
    Activation of ERbeta hijacks the splicing machinery to trigger R-loop formation in triple-negative breast cancer.
    Proc Natl Acad Sci U S A. 2024;121:e2306814121.
    PubMed     Abstract available


  14. TAYLOR-PHILLIPS S, Jenkinson D, Stinton C, Kunar MA, et al
    Fatigue and vigilance in medical experts detecting breast cancer.
    Proc Natl Acad Sci U S A. 2024;121:e2309576121.
    PubMed     Abstract available


  15. LAMIA KA
    Telling time in tumor samples reveals diversity of clock disruption.
    Proc Natl Acad Sci U S A. 2024;121:e2401496121.
    PubMed    


    February 2024
  16. LAUBLI H
    Unraveling the impact of a glyco-immune checkpoint in bone metastasis.
    Proc Natl Acad Sci U S A. 2024;121:e2400499121.
    PubMed    


  17. LI SY, Hammarlund JA, Wu G, Lian JW, et al
    Tumor circadian clock strength influences metastatic potential and predicts patient prognosis in luminal A breast cancer.
    Proc Natl Acad Sci U S A. 2024;121:e2311854121.
    PubMed     Abstract available


  18. ZIKRY TM, Wolff SC, Ranek JS, Davis HM, et al
    Cell cycle plasticity underlies fractional resistance to palbociclib in ER+/HER2- breast tumor cells.
    Proc Natl Acad Sci U S A. 2024;121:e2309261121.
    PubMed     Abstract available


    January 2024
  19. BAGHDASARYAN A, Liu H, Ren F, Hsu R, et al
    Intratumor injected gold molecular clusters for NIR-II imaging and cancer therapy.
    Proc Natl Acad Sci U S A. 2024;121:e2318265121.
    PubMed     Abstract available


  20. WANG Y, Xu Z, Wu KL, Yu L, et al
    Siglec-15/sialic acid axis as a central glyco-immune checkpoint in breast cancer bone metastasis.
    Proc Natl Acad Sci U S A. 2024;121:e2312929121.
    PubMed     Abstract available


  21. CENCIC R, Im YK, Naineni SK, Moustafa-Kamal M, et al
    A second-generation eIF4A RNA helicase inhibitor exploits translational reprogramming as a vulnerability in triple-negative breast cancer.
    Proc Natl Acad Sci U S A. 2024;121:e2318093121.
    PubMed     Abstract available


  22. SOLAIMUTHU B, Khatib A, Tanna M, Karmi A, et al
    The exostosin glycosyltransferase 1/STAT3 axis is a driver of breast cancer aggressiveness.
    Proc Natl Acad Sci U S A. 2024;121:e2316733121.
    PubMed     Abstract available


    December 2023
  23. HASSIN O, Sernik M, Seligman A, Vogel FCE, et al
    p53 deficient breast cancer cells reprogram preadipocytes toward tumor-protective immunomodulatory cells.
    Proc Natl Acad Sci U S A. 2023;120:e2311460120.
    PubMed     Abstract available


  24. WANG S, Bohnert V, Joseph AJ, Sudaryo V, et al
    ENPP1 is an innate immune checkpoint of the anticancer cGAMP-STING pathway in breast cancer.
    Proc Natl Acad Sci U S A. 2023;120:e2313693120.
    PubMed     Abstract available


  25. NISHIDA J, Cristea S, Bodapati S, Puleo J, et al
    Peripheral blood TCR clonotype diversity as an age-associated marker of breast cancer progression.
    Proc Natl Acad Sci U S A. 2023;120:e2316763120.
    PubMed     Abstract available


    October 2023
  26. CARUSO JA, Wang X, Murrow LM, Rodriguez CI, et al
    Loss of PPARgamma activity characterizes early protumorigenic stromal reprogramming and dictates the therapeutic window of opportunity.
    Proc Natl Acad Sci U S A. 2023;120:e2303774120.
    PubMed     Abstract available


    September 2023
  27. ANG HX, Sutiman N, Deng XL, Liu A, et al
    Cooperative regulation of coupled oncoprotein synthesis and stability in triple-negative breast cancer by EGFR and CDK12/13.
    Proc Natl Acad Sci U S A. 2023;120:e2221448120.
    PubMed     Abstract available


    August 2023
  28. DIBRA D, Moyer SM, El-Naggar AK, Qi Y, et al
    Triple-negative breast tumors are dependent on mutant p53 for growth and survival.
    Proc Natl Acad Sci U S A. 2023;120:e2308807120.
    PubMed     Abstract available


  29. MIYATA K, Zhou X, Nishio M, Hanyu A, et al
    Chromatin conformational changes at human satellite II contribute to the senescence phenotype in the tumor microenvironment.
    Proc Natl Acad Sci U S A. 2023;120:e2305046120.
    PubMed     Abstract available


    June 2023
  30. HAN SJ, Jain P, Gilad Y, Xia Y, et al
    Steroid receptor coactivator 3 is a key modulator of regulatory T cell-mediated tumor evasion.
    Proc Natl Acad Sci U S A. 2023;120:e2221707120.
    PubMed     Abstract available


  31. DRULA R, Pardini B, Fu X, De Los Santos MC, et al
    17beta-estradiol promotes extracellular vesicle release and selective miRNA loading in ERalpha-positive breast cancer.
    Proc Natl Acad Sci U S A. 2023;120:e2122053120.
    PubMed     Abstract available


    May 2023
  32. KIM JH, Park S, Jung E, Shin J, et al
    A dual-action niclosamide-based prodrug that targets cancer stem cells and inhibits TNBC metastasis.
    Proc Natl Acad Sci U S A. 2023;120:e2304081120.
    PubMed     Abstract available


    April 2023
  33. GUPTA M, Walters BA, Katsara O, Granados Blanco K, et al
    eIF2Bdelta blocks the integrated stress response and maintains eIF2B activity and cancer metastasis by overexpression in breast cancer stem cells.
    Proc Natl Acad Sci U S A. 2023;120:e2207898120.
    PubMed     Abstract available


    March 2023
  34. GUARDIA T, Zhang Y, Thompson KN, Lee SJ, et al
    OBSCN restoration via OBSCN-AS1 long-noncoding RNA CRISPR-targeting suppresses metastasis in triple-negative breast cancer.
    Proc Natl Acad Sci U S A. 2023;120:e2215553120.
    PubMed     Abstract available


  35. YAMAMOTO A, Huang Y, Krajina BA, McBirney M, et al
    Metastasis from the tumor interior and necrotic core formation are regulated by breast cancer-derived angiopoietin-like 7.
    Proc Natl Acad Sci U S A. 2023;120:e2214888120.
    PubMed     Abstract available


    February 2023
  36. BASSEY-ARCHIBONG BI, Rajendra Chokshi C, Aghaei N, Kieliszek AM, et al
    An HLA-G/SPAG9/STAT3 axis promotes brain metastases.
    Proc Natl Acad Sci U S A. 2023;120:e2205247120.
    PubMed     Abstract available


  37. ZHANG Z, Lu YX, Liu F, Sang L, et al
    lncRNA BREA2 promotes metastasis by disrupting the WWP2-mediated ubiquitination of Notch1.
    Proc Natl Acad Sci U S A. 2023;120:e2206694120.
    PubMed     Abstract available


    January 2023
  38. ITAH Z, Chaudhry S, Raju Ponny S, Aydemir O, et al
    HER2-driven breast cancer suppression by the JNK signaling pathway.
    Proc Natl Acad Sci U S A. 2023;120:e2218373120.
    PubMed     Abstract available


  39. CHEN X, Sifakis EG, Robertson S, Neo SY, et al
    Breast cancer patient-derived whole-tumor cell culture model for efficient drug profiling and treatment response prediction.
    Proc Natl Acad Sci U S A. 2023;120:e2209856120.
    PubMed     Abstract available


    December 2022
  40. LIN WC, Lin FT
    Super-enhanced MARCO variant drives triple-negative breast cancer progression.
    Proc Natl Acad Sci U S A. 2022;119:e2217953119.
    PubMed    


    November 2022
  41. YANG YS, Jin X, Li Q, Chen YY, et al
    Superenhancer drives a tumor-specific splicing variant of MARCO to promote triple-negative breast cancer progression.
    Proc Natl Acad Sci U S A. 2022;119:e2207201119.
    PubMed     Abstract available


  42. YU X, Zhang Y, Xiong S, McDaniel JM, et al
    Omics analyses of a somatic Trp53(R245W/+) breast cancer model identify cooperating driver events activating PI3K/AKT/mTOR signaling.
    Proc Natl Acad Sci U S A. 2022;119:e2210618119.
    PubMed     Abstract available


    October 2022
  43. TU Z, Hu Y, Raizada D, Bassal MA, et al
    Long noncoding RNA-mediated activation of PROTOR1/PRR5-AKT signaling shunt downstream of PI3K in triple-negative breast cancer.
    Proc Natl Acad Sci U S A. 2022;119:e2203180119.
    PubMed     Abstract available


  44. MICALIZZI DS, Che D, Nicholson BT, Edd JF, et al
    Targeting breast and pancreatic cancer metastasis using a dual-cadherin antibody.
    Proc Natl Acad Sci U S A. 2022;119:e2209563119.
    PubMed     Abstract available


  45. GARAN LAW, Xiao Y, Lin WC
    14-3-3tau drives estrogen receptor loss via ERalpha36 induction and GATA3 inhibition in breast cancer.
    Proc Natl Acad Sci U S A. 2022;119:e2209211119.
    PubMed     Abstract available


    September 2022
  46. ZHOU C, Wang D, Li J, Wang Q, et al
    TGFB2-AS1 inhibits triple-negative breast cancer progression via interaction with SMARCA4 and regulating its targets TGFB2 and SOX2.
    Proc Natl Acad Sci U S A. 2022;119:e2117988119.
    PubMed     Abstract available



  47. Correction for Lan et al., Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment.
    Proc Natl Acad Sci U S A. 2022;119:e2210925119.
    PubMed    



  48. Retraction for Gilkes et al., Hypoxia-inducible factors mediate coordinated RhoA-ROCK1 expression and signaling in breast cancer cells.
    Proc Natl Acad Sci U S A. 2022;119:e2213288119.
    PubMed    



  49. Retraction for Samanta et al., Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells.
    Proc Natl Acad Sci U S A. 2022;119:e2213289119.
    PubMed    


  50. KUMAR S, Das S, Sun J, Huang Y, et al
    Mixed lineage kinase 3 and CD70 cooperation sensitize trastuzumab-resistant HER2(+) breast cancer by ceramide-loaded nanoparticles.
    Proc Natl Acad Sci U S A. 2022;119:e2205454119.
    PubMed     Abstract available


    August 2022
  51. ROSHANZAMIR F, Robinson JL, Cook D, Karimi-Jafari MH, et al
    Metastatic triple negative breast cancer adapts its metabolism to destination tissues while retaining key metabolic signatures.
    Proc Natl Acad Sci U S A. 2022;119:e2205456119.
    PubMed     Abstract available


  52. DING X, Sharko AC, McDermott MSJ, Schools GP, et al
    Inhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in vitro and in vivo.
    Proc Natl Acad Sci U S A. 2022;119:e2201073119.
    PubMed     Abstract available


  53. ONG LT, Lee WC, Ma S, Oguz G, et al
    IFI16-dependent STING signaling is a crucial regulator of anti-HER2 immune response in HER2+ breast cancer.
    Proc Natl Acad Sci U S A. 2022;119:e2201376119.
    PubMed     Abstract available


    July 2022
  54. COELHO DR, Palma FR, Paviani V, He C, et al
    Nuclear-localized, iron-bound superoxide dismutase-2 antagonizes epithelial lineage programs to promote stemness of breast cancer cells via a histone demethylase activity.
    Proc Natl Acad Sci U S A. 2022;119:e2110348119.
    PubMed     Abstract available


  55. SOYAMA H, Nishio M, Otani J, Sakuma T, et al
    Hippo-TAZ signaling is the master regulator of the onset of triple-negative basal-like breast cancers.
    Proc Natl Acad Sci U S A. 2022;119:e2123134119.
    PubMed     Abstract available


  56. QIU Z, Guo W, Dong B, Wang Y, et al
    EBF1 promotes triple-negative breast cancer progression by surveillance of the HIF1alpha pathway.
    Proc Natl Acad Sci U S A. 2022;119:e2119518119.
    PubMed     Abstract available


    June 2022
  57. WANG G, Kumar A, Ding W, Korangath P, et al
    Intraductal administration of transferrin receptor-targeted immunotoxin clears ductal carcinoma in situ in mouse models of breast cancer-a preclinical study.
    Proc Natl Acad Sci U S A. 2022;119:e2200200119.
    PubMed     Abstract available


    May 2022
  58. LIU W, Sun P, Xia L, He X, et al
    A brain-enriched lncRNA shields cancer cells from immune-mediated killing for metastatic colonization in the brain.
    Proc Natl Acad Sci U S A. 2022;119:e2200230119.
    PubMed     Abstract available


    April 2022
  59. TKACH M, Thalmensi J, Timperi E, Gueguen P, et al
    Extracellular vesicles from triple negative breast cancer promote pro-inflammatory macrophages associated with better clinical outcome.
    Proc Natl Acad Sci U S A. 2022;119:e2107394119.
    PubMed     Abstract available


  60. HABARA M, Sato Y, Goshima T, Sakurai M, et al
    FKBP52 and FKBP51 differentially regulate the stability of estrogen receptor in breast cancer.
    Proc Natl Acad Sci U S A. 2022;119:e2110256119.
    PubMed     Abstract available


  61. AN W, Lin H, Ma L, Zhang C, et al
    Progesterone activates GPR126 to promote breast cancer development via the Gi pathway.
    Proc Natl Acad Sci U S A. 2022;119:e2117004119.
    PubMed     Abstract available


    March 2022
  62. HUANG Y, Du S, Liu J, Huang W, et al
    Diagnosis and prognosis of breast cancer by high-performance serum metabolic fingerprints.
    Proc Natl Acad Sci U S A. 2022;119:e2122245119.
    PubMed     Abstract available


  63. ZHANG S, Nelson OD, Price IR, Zhu C, et al
    Long-chain fatty acyl coenzyme A inhibits NME1/2 and regulates cancer metastasis.
    Proc Natl Acad Sci U S A. 2022;119:e2117013119.
    PubMed     Abstract available


    February 2022
  64. REN Z, Liang H, Galbo PM Jr, Dharmaratne M, et al
    Redox signaling by glutathione peroxidase 2 links vascular modulation to metabolic plasticity of breast cancer.
    Proc Natl Acad Sci U S A. 2022;119.
    PubMed     Abstract available


  65. ZHANG R, Yang Y, Dong W, Lin M, et al
    D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1.
    Proc Natl Acad Sci U S A. 2022;119.
    PubMed     Abstract available


  66. KARMI O, Marjault HB, Bai F, Roy S, et al
    A VDAC1-mediated NEET protein chain transfers [2Fe-2S] clusters between the mitochondria and the cytosol and impacts mitochondrial dynamics.
    Proc Natl Acad Sci U S A. 2022;119.
    PubMed     Abstract available


  67. MA C, He D, Tian P, Wang Y, et al
    miR-182 targeting reprograms tumor-associated macrophages and limits breast cancer progression.
    Proc Natl Acad Sci U S A. 2022;119.
    PubMed     Abstract available


  68. LIU B, Liu X, Han L, Chen X, et al
    BRD4-directed super-enhancer organization of transcription repression programs links to chemotherapeutic efficacy in breast cancer.
    Proc Natl Acad Sci U S A. 2022;119.
    PubMed     Abstract available


  69. BENHAMOU RI, Suresh BM, Tong Y, Cochrane WG, et al
    DNA-encoded library versus RNA-encoded library selection enables design of an oncogenic noncoding RNA inhibitor.
    Proc Natl Acad Sci U S A. 2022;119.
    PubMed     Abstract available


    January 2022

  70. Correction for Yi et al., Transcriptional suppression of AMPKalpha1 promotes breast cancer metastasis upon oncogene activation.
    Proc Natl Acad Sci U S A. 2022;119.
    PubMed    


  71. WANG Z, Moresco P, Yan R, Li J, et al
    Carcinomas assemble a filamentous CXCL12-keratin-19 coating that suppresses T cell-mediated immune attack.
    Proc Natl Acad Sci U S A. 2022;119.
    PubMed     Abstract available


    November 2021

  72. Correction for Wolfsberger et al., TAp73 represses NF-kappaB-mediated recruitment of tumor-associated macrophages in breast cancer.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed    


  73. SABHERWAL N, Rowntree A, Marinopoulou E, Pettini T, et al
    Differential phase register of Hes1 oscillations with mitoses underlies cell-cycle heterogeneity in ER(+) breast cancer cells.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


  74. ERDELYI K, Ditroi T, Johansson HJ, Czikora A, et al
    Reprogrammed transsulfuration promotes basal-like breast tumor progression via realigning cellular cysteine persulfidation.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


  75. MASAKI T, Habara M, Sato Y, Goshima T, et al
    Calcineurin regulates the stability and activity of estrogen receptor alpha.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


  76. LIU X, Xie P, Hao N, Zhang M, et al
    HIF-1-regulated expression of calreticulin promotes breast tumorigenesis and progression through Wnt/beta-catenin pathway activation.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


    October 2021
  77. TAKEUCHI Y, Kimura N, Murayama T, Machida Y, et al
    The membrane-linked adaptor FRS2beta fashions a cytokine-rich inflammatory microenvironment that promotes breast cancer carcinogenesis.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


  78. GHOSH M, Das S
    PRAMEF2-mediated dynamic regulation of YAP signaling promotes tumorigenesis.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


    September 2021
  79. KUMAR D, Mishra A, Lisok A, Kureshi R, et al
    Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


    August 2021
  80. MIN J, Nwachukwu JC, Min CK, Njeri JW, et al
    Dual-mechanism estrogen receptor inhibitors.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


  81. KANG E, Kadoch C, Rubenstein JL, Lanier LL, et al
    A functional mammalian display screen identifies rare antibodies that stimulate NK cell-mediated cytotoxicity.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


    July 2021
  82. LIU Z, Wang F, Liu X, Sang Y, et al
    Cell membrane-camouflaged liposomes for tumor cell-selective glycans engineering and imaging in vivo.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


  83. GOYETTE MA, Elkholi IE, Apcher C, Kuasne H, et al
    Targeting Axl favors an antitumorigenic microenvironment that enhances immunotherapy responses by decreasing Hif-1alpha levels.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


    June 2021
  84. VENCES-CATALAN F, Rajapaksa R, Kuo CC, Miller CL, et al
    Targeting the tetraspanin CD81 reduces cancer invasion and metastasis.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.